FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors? July 27, 2021 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 10 Ways to Provide Support During Breast Cancer Awareness Month September 27, 2019 Load more HOT NEWS 5 questions the NHS Workforce Plan for England needs to answer FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce
